Invited letter MUC4 mutations as an amplifier of complement-mediated thrombosis in paroxysmal nocturnal haemoglobinuria

Eng Soo Yap; Edwin Wei Sheng Thong; Cheryl Xiu Qi Lim

doi:10.1002/ctd2.70130

Clinical and Translational Discovery ›› 2026, Vol. 6 ›› Issue (2) :e70130 DOI: 10.1002/ctd2.70130

INVITED LETTER

Invited letter MUC4 mutations as an amplifier of complement-mediated thrombosis in paroxysmal nocturnal haemoglobinuria

Author information +

History +

PDF (157KB)

Cite this article

Download citation ▾

Eng Soo Yap, Edwin Wei Sheng Thong, Cheryl Xiu Qi Lim. Invited letter MUC4 mutations as an amplifier of complement-mediated thrombosis in paroxysmal nocturnal haemoglobinuria. Clinical and Translational Discovery, 2026, 6 (2) : e70130 DOI:10.1002/ctd2.70130

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1304-1309.

[2]	de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099-3106.

[3]	Valsami S, Grünewald B, Brodsky RA, Peffault de Latour R, Risitano AM. Thrombosis in paroxysmal nocturnal hemoglobinuria: from pathogenesis to treatment. Int J Mol Sci. 2024;25(22):12104.

[4]	Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-1243.

[5]	Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-6792.

[6]	Chen YY, Liu H, Li LY, et al. Role and clinical significance of MUC4 gene mutations in thrombotic events in patients with classic paroxysmal nocturnal hemoglobinuria. Zhonghua Xue Ye Xue Za Zhi. 2023;44(7):561-566. Chinese

[7]	Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653-1662.

[8]	Chen Y, Che M, Wang C, et al. MUC4 mutations promote a thrombotic phenotype in patients with paroxysmal nocturnal haemoglobinuria by increasing the deposition of terminal complement. Clin Transl Med. 2026;16(1):e70567.

[9]	Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037.

[10]	Peffault de Latour R, Röth A, Kulasekararaj AG, et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2024;390(11):994-1008.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.